RxDoctor Payments Data

Jennifer Fiorini, NP

Adult Health · Glens Falls, NYNPI 1780981589

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $131,941 of the $151,172 with a category attached, or 87.3%. AbbVie accounts for 91.0% of it on its own, with 18 other manufacturers making up the rest. Among adult health clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$151,172in general payments, 2019–2025

Across 597 payments — averaging $253.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$138K
  • Pfizer$7K
  • Biohaven Pharmaceutical Holding Company Ltd.$4K
  • Biohaven Pharmaceuticals, Inc.$789
  • Teva Pharmaceuticals USA, Inc.$626
  • Amgen$295
  • plus $963 from 13 others

What the payments were for

  • Consulting fees$3,4902%
  • Speaking & faculty fees$131,94187%
  • Travel & lodging$6,9625%
  • Food & beverage$8,7136%
  • Education$650%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$151,172 in reported general payments places this provider in the 95th percentile of 3,828 adult health providers in New York.

See all adult health providers in New York

Medicare billing

Part B allowed, 2024
$7,349
Medicare patients
28
Services billed
81

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UbrelvyUbrogepant134$194,440
Nurtec OdtRimegepant Sulfate71$83,870
QuliptaAtogepant53$65,984
Ajovy AutoinjectorFremanezumab-Vfrm65$54,654
Emgality PenGalcanezumab-Gnlm48$35,926
Ondansetron OdtOndansetron53$972
RizatriptanRizatriptan Benzoate26$350

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta$137,570$260,424187 claims
PfizerNurtec Odt$7,319$83,87071 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,828 adult health providers in New York.

Other adult health in Glens Falls

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →